Company ProfilePremium

Nagase & Co., Ltd.

Company Profile Analysis

長瀬産業株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nagase & Co., Ltd. - Company showcase

Year Founded & Workforce

1832

7,756 Employees

Nagase & Co., Ltd. logo

Nagase & Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nagase & Co., Ltd. Overview

Nagase & Co. is Japan's oldest and largest independent specialty-chemicals trading house. Founded in Kyoto in 1832, it is preparing for its bicentennial in 2032. Over the past two decades it has turned from a pure distributor into a hybrid "trading × manufacturing × R&D" group. The trading core sells resins, specialty chemicals, electronic and battery materials, automotive materials, food ingredients and pharmaceutical intermediates across about 30 countries. Captive manufacturers sit behind it:

  • Nagase ChemteX: formulated epoxy resins and liquid encapsulants for AI semiconductors

  • Nagase Viita (ex-Hayashibara): trehalose, pullulan and enzymes

  • Prinova Group (US): food and nutrition ingredients, premixes and contract manufacturing

  • Pac Tech (Germany): wafer bumping

  • Recently acquired Nagase Circrea (ex-SACHEM Asia): high-purity chemicals and TMAH developer recycling

  • Recently acquired Nagase Diagnostics (ex-Asahi Kasei Pharma diagnostics)

FY2026 net sales were ¥972.8 billion and operating income ¥44.7 billion, both records, with ROE of 8.0%. The investment case rests on mix-shift toward higher-margin proprietary materials, ROIC discipline and a 100% total-payout capital policy.


Company's own description

In the Yuho and integrated report, Nagase describes itself as a materials company that "solves manufacturing challenges through materials." It combines three functions:

Trading: information "discernment" (目利き), problem discovery and matching, and a global network

Manufacturing: proprietary materials and technology, quality control, customisation

R&D: new-material and application development

The internal maxim is "When in trouble, ask NAGASE" (「困ったらNAGASEに聞け!」). The Yuho states that the group's main activities are import, export and domestic trading of goods, plus manufacture and sale of products and provision of services across a wide range of industrial sectors.

For FY2026 the group reported through five segments: Functional Materials, Advanced Materials & Processing, Electronics & Energy, Mobility, and Life & Healthcare. From FY2027 (April 2026) these were consolidated into three segments:

Materials: Functional Materials + Advanced Materials & Processing + Mobility

Electronics: former Electronics & Energy

Life Sciences: former Life & Healthcare

(FY2027 Q1 Financial Briefing, 4 Aug 2026.)

Business model and revenue model

MetricTradingManufacturing
Gross profit (JPY 100M)1,324552
Operating income (JPY 100M)333113
Share of operating income~75%~25%

Nagase earns revenue in two ways that it now discloses separately.

(a) Trading business. Nagase and its sales subsidiaries buy and resell chemicals, resins, materials and ingredients. Margin comes from the spread plus technical-service and supply-chain value. Trading gross margins are typically mid-teens percent. Trading also books the sales of certain captive manufacturers' products, because Nagase handles their sales function.

(b) Manufacturing business. The aggregate of manufacturing subsidiaries, including Nagase ChemteX Group, Nagase Viita, Prinova's manufacturing arm, Pac Tech and Nagase RooTAC. Gross margins run ~35–40% at Nagase ChemteX and Nagase Viita.

In FY2026 (restated, company basis):

(FY2027 Q1 Briefing, quarterly appendix.)

The revenue model is overwhelmingly product sales, both distribution and manufactured goods. Service revenue includes:

  • contract bumping services (Pac Tech)

  • contract manufacturing and premix "Solutions" (Prinova)

  • LCD glass-thinning processing (Nagase Electronic Technology Xiamen)

  • radiation-dosimetry services (Nagase-Landauer, equity method)

  • TMAH developer collection and recycling (Nagase Circrea)

There is no material subscription or licensing revenue; a split by revenue type is not publicly disclosed.

Value-chain position

Nagase sits mid-stream. It sources from global chemical majors (historically Ciba-Geigy, Union Carbide, Eastman Kodak, GE) and from its own plants. It sells to converters, compounders and OEMs in electronics/semiconductors, automotive, coatings and inks, plastics processing, food and beverages, cosmetics, and pharmaceuticals and diagnostics. Its differentiation is formulation know-how, application development (Nagase Application Workshop, Amagasaki) and supply-chain resilience. The last point was shown in Q1 FY2027, when Nagase sourced substitute petrochemicals during the Strait of Hormuz-related naphtha shortage (FY2027 Q1 Briefing).

Customer types and end-markets (FY2026 segment basis)

End-marketPrimary segment(s)FY2026 demand commentary (company)
Electrical & electronic equipmentAdvanced Materials & Processing / MaterialsDemand and resin market conditions grew slightly YoY
AutomobilesMobility / MaterialsEV demand declined; slight overall decrease YoY
CoatingsFunctional Materials / MaterialsAutomotive and construction applications decreased slightly
SemiconductorsElectronics & Energy / ElectronicsAI-driven growth; China domestic production expanding; overall favourable
SmartphonesElectronicsOverall market flat YoY due to slowdown in China
FoodLife & Healthcare / Life SciencesStrong in Japan; favourable in Europe and US
CosmeticsLife SciencesStructural change from weak China demand
Medical / pharmaLife SciencesAdditive, API and intermediate demand strong

(FY2027 Q1 Briefing, "Business Environment Surrounding NAGASE Segments".)

Independent characterisation

Nagase is best read as a specialty distributor with an embedded portfolio of niche manufacturers. It is not a sogo shosha. Its consolidated operating margin (4.6% in FY2026) is structurally capped by the trading mix. Value creation depends on three things:

  • the faster-growing, higher-margin manufacturing assets: Nagase ChemteX (operating margin 11.5% in FY2026, 17.1% in Q1 FY2027) and Nagase Viita (16.5% before goodwill amortisation)

  • returning Prinova (operating margin 3.3%; ¥214.2bn sales in FY2026) to its acquisition-case returns

  • disciplined capital allocation, now explicitly ROIC-driven

The business is cyclical in its trading spreads (resin and chemical market prices) but diversified across end-markets. The Life Sciences leg (~32% of sales) gives some defensiveness.

Strategy

Long-term vision

The vision is "Ideal NAGASE 2032": a "Business Designer that Creates a Sustainable Future", timed to the 200th anniversary. The management philosophy is "walking the right path with sincerity"; the stated vision is creating a safe, secure and warm society in which people can live comfortably (CEO message, Apr 2023).

ACE 2.0 (FY2022–FY2026) — outcome

ACE 2.0 KGITargetFY2026 actualResult
ROE≥8.0%8.0%Achieved
Operating income¥35.0bn¥44.7bnExceeded
Total payout ratio (time-limited)100%100.7% (FY2026); 105.4% (FY2025)Achieved
Cross-shareholding reduction~¥30bn over 5 yearsOngoing; gains on sale ¥2.8bn (FY2025), ¥3.5bn (FY2026)Progressing
Scope 1+2 GHG reduction vs FY2013≥37% (2022 KPI); later 46% by 203043% achieved (FY2025, Integrated Report 2025)Ahead of interim KPI
Engagement survey score≥67 total score (revised KPI)——

The plan's theme was "Pursuit of Quality" under three pillars: Accountability, Commitment, Efficiency. Businesses were classified into four quadrants:

Foundation: (基盤)

Focus: (注力): proprietary products and technologies to lift profitability

Development: (育成): bio R&D, semiconductors, food, life sciences, new products, Global South; potential investment ≈ ¥80bn from FY2024 (Kitaishihon summary)

Improvement: (改善): fix or exit

(Integrated Report 2025 via Kitaishihon; Envalith; company KPI notice, May 2022.)

"Walk the Talk 2028" (FY2027–FY2029), announced 7 May 2026

ElementDetail
Profit targetOperating income above ¥50.0bn by the final year (FY2029, company "fiscal 2028")
Return targetROE ≥9.0%
EPSGuideline of +30% EPS growth over three years (≈9% CAGR from ¥78.89)
Market valueAspiration of a ¥1 trillion market capitalisation (FilingReader summary; timeframe not specified in sources)
Growth investment¥100bn, focused on expanding semiconductor materials and improving nutrition-business efficiency (Prinova)
Shareholder returns100% total payout ratio; progressive "stable dividend increases" over three years; flexible buybacks
FundingSale of policy (cross-) shareholdings
StructureFive segments consolidated into three (Materials, Electronics, Life Sciences) from April 2026

Initiatives in the last 24 months

InitiativeDateDescriptionStatus
Nagase DiagnosticsAnnounced Sep 2024; live 1 Jul 2025Acquired Asahi Kasei Pharma's diagnostics business and Ohito plant; Focus (life-science manufacturing) and Development (biotech)Consolidated FY2026
SACHEM Asia / Nagase CircreaAnnounced Mar 2025; closed 2 Jun 2025High-purity chemicals and TMAH developer recycling (circular economy × semiconductors)Integrated and renamed Mar–Apr 2026
Prinova — AplinovaApr 2025Brazil ingredients distribution; Global South pushConsolidated (Apliquimica)
Nagase Wahlee IndiaAnnounced May 2025; ops Jun 2025Resin sales JV (NWP Taiwan × Nagase India), targeting China/Taiwan supply-chain relocation to IndiaConsolidated
Nagase India Pune branch1 Dec 2025Automotive and chemical cluster coverageOperating
India semiconductor logistics with Nippon ExpressJan 2026High-tech supply chain for front-end semiconductor materials in Dholera, Gujarat (GlobalData)Announced
California biotech labJan 2026Robotics- and AI-driven new-material discoveryOpened
Nagase ChemteX capacityFY2026Capacity expansion for modified epoxy resins and liquid encapsulants for AI semiconductors; a-SMC development (Envalith summary)Small-volume a-SMC production (Q1 FY2027)
Dodai Group stakeApr 2026Partial share acquisition (GlobalData). Dodai is understood to be an e-mobility start-upUnconfirmed details
Prinova Nutrition efficiency programmeFY2025–FY2027Loss reduction in Nutrition; separate manufacturing/trading disclosure from FY2027Loss narrowing
Materiality revisionSep 2024Added healthy-lifespan extension, supply-chain sustainability and circular economy to engagement, decarbonisation and governanceAdopted
Capital policyFY2025–FY20274:1 split (Apr 2026); buybacks ¥17.0bn (FY2025), ¥23.0bn (FY2026), ¥3.0bn (Aug–Sep 2026)Ongoing

Management guidance (FY2027, unchanged at Q1, 4 Aug 2026)

Guidance item (JPY 100M)FY2026 actualFY2027 guidance
Net sales9,72710,000
Gross profit1,8761,980
SG&A1,4291,530
Operating income447450
Operating income excl. actuarial effect450409
Ordinary income440450
Profit attributable to owners331345
EPS (JPY)78.8984.59
DPS (JPY)25.0027.00

Assumptions:

  • USD/JPY 155.0; RMB/JPY 22.5

  • Sensitivity of operating income to a ¥1 depreciation: USD +¥50m, RMB +¥400m

Q1 FY2027 progress: the first quarter achieved 38% of full-year operating income guidance (¥17.0bn) and 42% of net income guidance. Management will reassess the forecast at the H1 results in early November 2026 because of Middle East uncertainty.

Products & Services

Pricing models are not publicly disclosed for any product line. Nagase sells B2B on negotiated, mostly spot or contract pricing. "Launch year" is given where disclosed.

Functional Materials → Materials (from FY2027)

Product lineDescription / capabilitiesTarget customerNotes / flagship
Coating & ink raw materialsResins, pigments, dispersions, additives for automotive, construction and industrial coatings and printing inksPaint and ink makersFY2026 sales declined on weak automotive and construction demand (Envalith summary of Yuho)
Urethane raw materials & auxiliariesPolyols/isocyanate-related materials, release agentsUrethane foam converters (construction, automotive, industrial)Equity affiliate Cytech Products (Kentucky, 35%) makes urethane release agents
Semiconductor material raw materials / electronics chemicalsHigh-purity chemicals, electronics chemicals, fluorine chemicalsSemiconductor and electronic-material makersFY2026 growth area within the segment
Specialty epoxy, solvents, siliconesUpstream intermediatesFormulatorsLong-standing agency relationships
Functional films/sheets, adhesives, sanitary materialsConverted and functional films; nonwoven/sanitary inputsHygiene, packaging, industrial—
Water treatment & environmental productsWater-treatment equipment, metal-organic frameworks (MOFs), CO2-capture equipmentIndustrial, environmentalDevelopment-stage new business

Advanced Materials & Processing → Materials

Product lineDescriptionTarget customerNotes
Engineering & commodity plasticsDistribution and compounding of thermoplastics (PC, PA, PBT, ABS etc.)E&E equipment, OA, appliances, automotive tier suppliersTaiwan JV Nagase Wahlee Plastics is a major Asian resin distributor; Nagase Wahlee India started June 2025
Thermosetting resins & synthetic-resin productsResin products and compoundsConvertersNagase Plastics Co. (Osaka)
Molding machines & moldsEquipment trading; equity affiliate Automotive Mold Technology (Rayong, 32.1%)Molders—
Packaging materialsFilms and packaging; Nafuko (Bangkok, 28%) packaging affiliateFMCG, food—
Industrial hoses & civil-engineering pipesManufactured by Nagase RooTAC IndustriesIndustrial and civil engineeringSales rose in Q1 FY2027
Digital-print processing materialsManufacturing businessPrintingNoted as weak in earlier periods (FY2023 briefing)
Colour masterbatchDainichi Color Vietnam (40%, equity method)Plastics processors—

Electronics & Energy → Electronics

Product lineDescription / key capabilitiesTarget customerNotes / flagship
Formulated (modified) epoxy resins — Nagase ChemteXEpoxy formulations incl. LMC (Liquid Molding Compound) for advanced semiconductor packagingOSATs, IDMs, AI-semiconductor supply chainLMC sales for AI semiconductors rose while mobile-device sales fell (Q1 FY2027)
a-SMC (Advanced Sheet Molding Compound)Encapsulant for high-performance IC package substratesAdvanced-package substrate makersAdopted; small-volume production started (Q1 FY2027 Briefing)
Photolithography materialsDevelopers, strippers and process chemicalsDisplay and semiconductor fabsSales flat; cost efficiencies lifted profit (Q1 FY2027)
Epichlorohydrin derivatives, conductive materials, functional dyesNagase ChemteX specialty chemistries (incl. Denacol-type epoxy compounds; brand per analyst knowledge)Industrial and electronics—
High-purity chemicals & catalysts — Nagase Circrea (ex-SACHEM Asia)High-purity chemicals for semiconductors, catalysts, specialty chemicals; Wuxi manufacturingSemiconductor and FPD fabs (China, Korea, Japan, Taiwan)Acquired June 2025
TMAH developer recovery & regenerationCollection and recycling of used TMAH developerTFT/FPD and semiconductor fabsDescribed as Japan's first TMAH recovery/regeneration business (Envalith summary of company IR); legacy SN Tech JV with SACHEM, ~15 years
Wafer bumping equipment & contract bumping — Pac TechLaser-based solder-ball and electroless plating bumpingSemiconductor packagingStrong bumping contract services (Q1 FY2027)
LCD glass thinningChemical etching of glass panel units (Nagase Electronic Technology, Xiamen)Display makers—
Display optical materials, touch-panel parts, abrasives, 3D-printing materialsTradingDisplay and electronics OEMsNagase Abrasive Materials deconsolidated in FY2026 (reason not disclosed)
Siloxane functional materials (Inkron)Functional materials for semiconductors and devicesDevice makersInkron Oy deconsolidated in FY2026; Inkron Limited (HK) remains a specified subsidiary
Precision plastic lenses & optical unitsNissei Technology (20%, equity method)Optics—
Nagase ChemteX Group (JPY 100M)FY2026FY2027F
Sales330356
Gross profit117125
Operating income3737

Nagase ChemteX Group financials (JPY 100M; restated to include Wuxi and America units):

Q1 FY2027 operating income was ¥1.7bn (17.1% margin) versus ¥0.9bn a year earlier.

Mobility → Materials

Product lineDescriptionTarget customerNotes
Automotive resins & functional materialsResins, functional paints, adhesives for interiors/exteriors and functional partsJapanese and global OEMs, tier-1sSolid in Q1 FY2027, partly on new adoptions
Battery & electrification materialsSecondary-battery materials, electrification componentsEV/battery supply chainWeak EV demand cited in FY2026
HMI / in-vehicle electronics componentsHuman-machine interface components, ADAS-related materialsTier-1s—
Seat-pad urethaneTQ-1 de Mexico (25%)Automotive seatingEquity method
Automotive parts (India)Uno Minda Kyoraku (20%, Haryana)Indian OEMsEquity method

Life & Healthcare → Life Sciences

Product lineDescription / capabilitiesTarget customerNotes / flagship
Prinova Group — ingredients distributionVitamins, amino acids, sweeteners, flavours, aroma chemicals, citrus oils etc.Food, beverage, nutrition, flavour housesTrading GP ¥23.9bn in FY2026; profit pressured by logistics costs in Q1 FY2027
Prinova — Solutions (premix and contract manufacturing)Custom nutrient premixes, powder blending, finished-product contract manufacturingNutrition and CPG brandsMain driver of manufacturing recovery in FY2026–FY2027
Prinova — Nutrition businessNutrition manufacturingNutrition brandsLoss narrowing on sales growth and efficiency (Q1 FY2027)
Prinova Latin AmericaAplinova (Brazil ingredients distribution, acquired Apr 2025); Flavor Tec (Brazil citrus-oil processor, acquired 2023)LATAM food and beverageFruttini Sucos de Frutas Ltda deconsolidated in FY2026
Prinova AsiaPrinova Solutions Asia (HK), Prinova nutrition technology (Changzhou)Asian food/nutrition—
Nagase Viita (ex-Hayashibara) — food ingredientsTrehalose (TREHA brand), pullulan, functional saccharides, phospholipidsFood processorsRaw-material inflation hit food margins in Q1 FY2027
Nagase Viita — cosmetics ingredientsFunctional actives incl. ascorbic-acid derivatives (e.g. AA2G; brand per analyst knowledge)Cosmetics makers (Japan and overseas)Volume up in Q1 FY2027
Nagase Viita — pharma additives & enzymesPharmaceutical excipients, industrial enzymesPharma, industry—
Bio-derived super-absorbent polymer (SAP)Biodegradable SAP for adult diapers, greening and agricultural water retentionHygiene, agricultureHighlighted in Integrated Report 2025
Pharmaceutical intermediates & APIsTrading of intermediates and APIsPharma (branded and generic)FY2027 Q1 sales flat
Nagase DiagnosticsDiagnostic reagents, diagnostic enzymes, life-science raw materialsIVD makersEx-Asahi Kasei Pharma diagnostics business plus Ohito plant; consolidated 1 Jul 2025; 205 employees at formation
Cosmetics/beauty careNagase Beauty Care Co.Consumers / brandsScale not disclosed
Radiation dosimetry serviceNagase-Landauer (50%, equity method)Hospitals, nuclear, industry—
Major manufacturing subsidiaries (JPY 100M)FY2026FY2027F
Nagase Viita sales346350
Nagase Viita operating income before goodwill/intangible amortisation5751
Nagase Viita operating income after amortisation3832
Prinova Group sales2,1422,420
Prinova Group operating income before amortisation6980
Prinova Group operating income after amortisation4251

Nagase Viita and Prinova Group (JPY 100M):

(FY2027 Q1 Briefing.)

Corporate / others

LineDescription
IT and functional servicesInformation processing and functional services (Nagase Business Expert etc.)
LogisticsSenko Nagase Logistics (15%, equity method; warehousing and transport, Amagasaki)
Dye tradingOG Nagase Color Chemical (50%, equity method)
Biotech R&D platformNagase Bio Innovation Center (Kobe); new California biotechnology lab using robotics and AI, opened Jan 2026 (Envalith summary of company IR)

Financial Narrative

Sources: Kessan Tanshin FY2026 (7 May 2026) for FY2025–FY2026. S&P Global Market Intelligence via StockAnalysis (data updated 30 Jun 2026) for FY2022–FY2024 and balance-sheet/cash-flow line items.

Comparability warnings:

Revenue recognition: FY2022 is the first year under Japan's new revenue-recognition standard (ASBJ No. 29). Its revenue is not comparable with FY2021 (¥830bn reported on the old gross basis).

Gross profit: FY2025 gross profit was restated retrospectively for an accounting-policy change, from ¥181,291m originally to ¥173,301m. Roughly ¥8.0bn of costs moved from SG&A into cost of sales; operating income was unchanged. FY2022–FY2024 gross profit is on the pre-change basis, so the reported gross margin uplift from FY2024 to FY2026 is understated, not overstated.

Income statement

Notes:

Diluted EPS: not presented by the company; no dilutive securities.

Ordinary income: ¥38,382m (FY2025) and ¥44,096m (FY2026), Kessan Tanshin.

EBITDA definition: analyst-defined. Matsui Securities shows FY2026 EBITDA of ¥61,636m on a different definition. This discrepancy is noted.

EPS sources: FY2022–FY2024 post-split EPS from ROIC.ai (S&P data), consistent with net income divided by about 4 × the pre-split average share count.

Margins

Growth rates FY2022→FY2026 (analyst calculation):

  • Revenue CAGR: 5.7% (¥780.6bn → ¥972.8bn)

  • Operating income CAGR: 6.1%

  • Net income CAGR: 6.3%

  • EPS CAGR: 10.3%, boosted by buybacks

Commentary. Three phases are visible.

FY2022–FY2024: margin compression: Operating income fell from ¥35.3bn to ¥30.6bn. Inflationary resin and chemical pricing in FY2022–FY2023 initially lifted sales (+17% in FY2023) but compressed margins. SG&A grew faster than gross profit (+29% vs +18% over two years) as Prinova's cost base expanded and wage and logistics costs rose. Inventory destocking hit electronics and automotive chemicals in FY2024.

FY2025: inflection: Operating income rose 27.6% to ¥39.1bn. Drivers were Electronics & Energy (+39% OI on semiconductor materials), Functional Materials (+50%) and ~¥3.5bn of actuarial gains in retirement-benefit expense. Life & Healthcare collapsed to ¥3.4bn on Prinova problems, including a ~¥1.3bn bad-debt provision in FY2025 Q2.

FY2026: record: Operating income reached ¥44.7bn (+14.5%) despite the actuarial swing turning to a ~¥0.3bn loss. Gross profit rose 8.3% on 2.9% sales growth (margin +1.0pt), the clearest evidence that the ROIC-driven mix strategy is working. Electronics & Energy (+20.8% OI, Nagase ChemteX AI-semiconductor epoxy) and the Life & Healthcare recovery (+187% OI as Prinova manufacturing turned around and Nagase Viita intangible amortisation partly ended) were the drivers. Net income rose 29.8% to ¥33.1bn, helped by:

  • ¥3.5bn gain on sale of investment securities (cross-shareholding unwinding)

  • ¥1.78bn gain on bargain purchase (attributable to the SACHEM Asia acquisition; analyst inference, as the company does not name the transaction)

  • a lower tax rate

Balance sheet

Company-defined measures (FY2026 Q1 FY2027 Briefing):

  • Interest-bearing debt: ¥191.0bn at 31 Mar 2026; ¥216.3bn at 30 Jun 2026

  • Net D/E ratio: 0.34 (Mar 2026); 0.39 (Jun 2026)

  • Shareholders' equity ratio: 48.8% (Mar 2026); 47.4% (Jun 2026)

FY2026 debt composition (Kessan Tanshin):

  • Short-term loans ¥20.2bn (down from ¥42.3bn)

  • Commercial paper ¥47.0bn (up from ¥19.5bn)

  • Current portion of long-term loans ¥15.0bn

  • Bonds ¥40.0bn

  • Long-term loans ¥50.0bn

  • Lease liabilities ¥16.1bn

Commentary. The balance sheet is conservative for a trading house: equity ratio ~49%, net D/E ~0.3x. Three FY2026 moves stand out:

  • Cash fell ¥20.5bn and net debt rose ¥36bn. The causes were acquisitions (¥19.1bn of subsidiary-share purchases), doubled capex (¥25.4bn) and ¥23.0bn of buybacks.

  • PP&E jumped from ¥91.7bn to ¥124.0bn on newly consolidated SACHEM Asia and Nagase Diagnostics assets and capacity additions.

  • Accumulated other comprehensive income rose ¥24.2bn (securities valuation +¥9.8bn, translation +¥11.3bn). Equity is therefore sensitive to the yen and to the cross-shareholding portfolio (investment securities ¥87.6bn).

Cash flow

Commentary. Nagase's cash flow is dominated by working capital, which is typical of distribution:

  • FY2022–FY2023: inflation absorbed ¥84bn of working capital and drove negative free cash flow.

  • FY2024: destocking released ¥35bn and produced a ¥58.9bn free-cash-flow peak.

  • FY2025–FY2026: normalised free cash flow of ~¥22–24bn per year.

Shareholder returns in those two years (¥26.6bn and ¥32.6bn) exceeded free cash flow, funded by asset sales (cross-shareholdings) and incremental debt. This is consistent with ACE 2.0's time-limited 100% total-payout policy.

Q1 FY2027 operating cash flow was −¥21.2bn, after a ¥30.6bn working-capital build on Middle East-driven price spikes and precautionary customer buying. That is a reminder of cash volatility.

Ratios

Notes:

  • Company-reported ROE: 6.4% (FY2025), 8.0% (FY2026).

  • The company's own ROIC definition differs. Its FY2026 forecast ROIC was 5.2% (Integrated Report 2025 via Kitaishihon).

Commentary. ROE has finally cleared the 8% ACE 2.0 hurdle. ROIC of roughly 5% sits close to a plausible WACC of 5–6% (company WACC not disclosed in the sources reviewed), so economic value creation is marginal. The new plan's ≥9% ROE target relies heavily on EPS accretion from buybacks and cross-shareholding sales, not only on operating improvement. The cash conversion cycle of ~125–130 days is long. Each 10 days of improvement would release about ¥27bn of cash at FY2026 sales levels (analyst calculation).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (FY2026) Overview

Segment (FY2026)ContentsPrincipal products / services

Functional Materials (機能素材)

Upstream functional chemicals

Coating and ink raw materials, pigments, additives, urethane raw materials and auxiliaries, electronics chemicals, high-purity chemicals, surfactants, specialty epoxy, solvents, silicones, functional films/sheets, sanitary materials, water-treatment products, MOFs, CO2-capture equipment

Advanced Materials & Processing (加工材料)

Plastics and processing

Engineering and commodity plastics, thermoplastic and thermosetting resins, synthetic-resin products, packaging materials, molding machines and molds, digital-print processing materials, industrial hoses and civil-engineering pipes (Nagase RooTAC)

Electronics & Energy (電子・エネルギー)

Electronics and semiconductor materials

Formulated/modified epoxy resins and liquid encapsulants (Nagase ChemteX), photolithography materials, high-purity chemicals and TMAH developer recycling (Nagase Circrea), wafer bumping equipment and contract services (Pac Tech), display optical materials, touch-panel components, LCD glass thinning (Xiamen), abrasive materials, 3D-printing materials

Mobility (モビリティ)

Automotive

Resins, functional paints, adhesives, battery and electrification materials, interior/exterior and functional-part materials, HMI components

Life & Healthcare (生活関連)

Food, cosmetics, pharma, diagnostics

Food ingredients (Prinova; Nagase Viita trehalose, pullulan), premixes and contract manufacturing, cosmetics raw materials, pharma intermediates and APIs, pharmaceutical additives, enzymes, diagnostic reagents (Nagase Diagnostics), health foods

Segment net sales (JPY Mn)

Segment net sales (JPY Mn)FY2022FY2023FY2024FY2025FY2026

Functional Materials

99,874156,161146,804153,746153,642

Advanced Materials & Processing

257,283220,955198,543210,627206,690

Electronics & Energy

128,131136,975144,758161,315172,891

Mobility

103,389125,560132,117132,091130,256

Life & Healthcare

191,634273,161277,779287,079309,207

Segment operating income (JPY Mn)

Segment operating income (JPY Mn)FY2022FY2023FY2024FY2025FY2026

Functional Materials

7,82310,4866,1589,2139,305

Advanced Materials & Processing

10,8587,6785,3136,6847,650

Electronics & Energy

10,2789,2738,85212,30214,859

Mobility

4,1314,7943,6144,2383,785

Life & Healthcare

9,42910,5818,0063,4239,832

Segment operating margin (%)

Segment operating margin (%)FY2022FY2023FY2024FY2025FY2026

Functional Materials

7.86.74.26.06.1

Advanced Materials & Processing

4.23.52.73.23.7

Electronics & Energy

8.06.86.17.68.6

Mobility

4.03.82.73.22.9

Life & Healthcare

4.93.92.91.23.2

Segment Revenue

SegmentSales YoY FY2025 (%)Sales YoY FY2026 (%)OI YoY FY2025 (%)OI YoY FY2026 (%)Share of sales FY2024 (%)Share of sales FY2025 (%)Share of sales FY2026 (%)

Functional Materials

4.7-0.149.61.016.316.315.8

Advanced Materials & Processing

6.1-1.925.814.522.122.321.2

Electronics & Energy

11.47.239.020.816.117.117.8

Mobility

0.0-1.417.3-10.714.714.013.4

Life & Healthcare

3.37.7-57.2187.230.930.431.8

Segment Overview

SegmentSegment assets (JPY Mn)Capex (JPY Mn)Depreciation (JPY Mn)EmployeesSegment ROA (%)

Functional Materials

122,4931,9498028727.6

Advanced Materials & Processing

116,2491,3668861,1446.6

Electronics & Energy

111,9544,5912,8051,61113.3

Mobility

70,0691712573015.4

Life & Healthcare

284,0776,4717,5182,6573.5

Revenue by Segment (JPY)

New segment (JPY 100M)FY2026 actual salesFY2026 actual GPFY2026 actual OIFY2027 forecast salesFY2027 forecast GPFY2027 forecast OI

Materials

4,9057572144,955776196

Electronics

1,7284531531,750479144

Life Sciences

3,092664863,29472472

Corporate & Others

01-70038

Total

9,7271,87644710,0001,980450

Segment Revenue (Quarterly)

New segmentQ1 FY2026 salesQ1 FY2027 salesQ1 FY2026 OIQ1 FY2027 OIOI YoY (%)

Materials

1,1891,403508163

Electronics

415491304960

Life Sciences

768902212937

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Net sales (JPY Mn)

780,557912,896900,149944,961972,783

Net sales growth YoY (%)

-6.017.0-1.45.02.9

Gross profit (JPY Mn)

139,495155,410164,719173,301187,687

SG&A incl. goodwill amortisation (JPY Mn)

104,231122,038134,100134,222142,959

Operating income (JPY Mn)

35,26433,37230,61939,07844,727

D&A incl. goodwill amortisation (JPY Mn)

13,69414,92216,62518,05119,599

EBITDA = OI + D&A (JPY Mn)

48,95848,29447,24457,12964,326

Interest expense (JPY Mn)

1,1763,2113,7443,7343,348

Income before income taxes (JPY Mn)

39,55733,13732,66538,13045,977

Profit attributable to owners of parent (JPY Mn)

25,93923,62522,40225,52133,119

EPS basic, post-split (JPY)

53.3649.8848.7457.6078.89

Dividend per share, post-split (JPY)

13.517.520.022.525.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

17.917.018.318.319.3

Operating margin

4.53.73.44.14.6

EBITDA margin

6.35.35.26.06.6

Net margin

3.32.62.52.73.4

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (JPY Mn)

739,720762,688792,336808,143871,526

Cash & deposits (JPY Mn)

54,21140,89759,41066,31045,599

Trade receivables (JPY Mn)

288,614301,084320,186310,203320,499

Inventories (JPY Mn)

157,524169,720147,990166,222177,559

Short-term debt incl. CP and current LTD (JPY Mn)

116,873105,173104,67767,84982,175

Long-term debt incl. bonds (JPY Mn)

48,24462,69747,53393,45490,000

Lease liabilities, long-term (JPY Mn)

09,76312,49211,47116,077

Total debt incl. leases (JPY Mn)

165,117177,633164,702172,774188,252

Net debt (JPY Mn)

110,906136,736105,292106,464142,653

Shareholders' equity (owners of parent) (JPY Mn)

344,261367,674394,064399,052425,445

Total net assets (JPY Mn)

355,091378,387401,314406,458434,023

Goodwill (JPY Mn)

29,49229,00427,88425,40028,384

Other intangibles (JPY Mn)

35,57839,92441,46540,41140,304

Working capital (JPY Mn)

206,450243,929239,795290,550269,311

Book value per share, post-split (JPY)

717.05784.81865.96919.771,043.19

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (JPY Mn)

-17,7769,41472,95936,32147,805

Change in working capital (JPY Mn)

-60,577-23,52135,391-5,552-3,379

Capex, PP&E (JPY Mn)

8,83012,02914,01912,55425,351

Free cash flow = OCF − PP&E capex (JPY Mn)

-26,606-2,61558,94023,76722,454

Acquisitions, net of cash (JPY Mn)

3,8480244019,071

Investing cash flow (JPY Mn)

-7,664-8,031-11,627-11,615-46,511

Dividends paid (JPY Mn)

5,8767,1509,2819,5579,604

Share buybacks (JPY Mn)

6,0065,6628,00117,01823,037

Financing cash flow (JPY Mn)

27,282-17,247-48,046-18,212-25,384

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, avg equity (%)

7.56.65.96.48.0

ROA, NI / avg assets (%)

3.53.12.93.23.9

ROIC, analyst: OI × (1 − 30%) / (net assets + net debt) (%)

5.34.54.25.35.4

Current ratio (x)

1.671.851.792.081.91

Total debt / equity (x)

0.480.480.420.430.44

Net debt / equity (x)

0.320.370.270.270.34

Net debt / EBITDA (x)

2.272.832.231.862.22

Interest coverage, OI / interest expense (x)

30.010.48.210.513.4

Asset turnover, sales / avg assets (x)

1.061.221.161.181.16

Days sales outstanding

135.0120.4129.8119.8120.3

Days inventory outstanding

89.781.873.478.682.6

Days payables outstanding

84.967.777.671.674.3

Cash conversion cycle (days)

139.8134.5125.6126.8128.6

Revenue by Region (%) and Revenue by Region

MetricFY2022FY2023FY2024FY2025FY2026

Overseas sales ratio (%)

67.370.170.170.469.8

Japan sales ratio, derived (%)

32.729.929.929.630.2

Implied overseas sales, analyst calc. (JPY Mn)

525,315639,940631,004665,253679,003

Implied Japan sales, analyst calc. (JPY Mn)

255,242272,956269,145279,708293,780

Region gross profit (JPY Mn)

Region gross profit (JPY Mn)Q1FY2026Q1FY2027

Domestic (incl. inter-regional adjustments)

20,90025,500

Greater China

6,7009,000

ASEAN

4,5005,700

Americas

8,2009,400

Europe

3,3004,800

Other

300400

Overseas total

23,30029,500

Valuation Snapshot

MetricValueSource

Last close

¥1,152 (29 Sep 2026)

Kabuyoho

52-week high / low

¥1,306 (5 Aug 2026) / ¥712.1 (22 Jul 2025)

Yahoo Finance JP; Kabuyoho

Move from 52-week low

+61.8%

Analyst calculation

1-year total return

Directionally strongly positive given the Jul 2025 low of ¥712

—

Pre-split all-time low reference

¥177.3 split-adjusted (13 Mar 2009)

Matsui

Valuation Multiples

MultipleNagaseBasis

P/E (trailing)

14.6x

EPS ¥78.89

P/E (forward, guidance)

13.6x

EPS ¥84.59

P/E (forward, consensus)

~11.6x

Consensus NI ¥40.65bn / ~408m shares ≈ EPS ¥99.7 (analyst calc.)

P/B

1.10x

BPS ¥1,043.19

EV/EBITDA (trailing)

~9.7x

EV ≈ ¥470bn mkt cap + ¥142.7bn net debt + ¥8.6bn minorities = ¥621bn; EBITDA ¥64.3bn

EV/Sales

~0.64x

—

Dividend yield (forecast)

2.3%

DPS ¥27

Peer Comparison

CompanyP/EP/BDividend yield

Nagase

13.30x1.08x2.40%

Macnica Holdings

16.49x1.89x2.71%

Iwatani

10.35x1.08x2.30%

Inabata

~10.2x (¥3,920 / FY2026 EPS ¥384.84; analyst calc.)

—

~3.6% on FY2027 DPS ¥143

Consensus Item Details

Consensus itemFY2027E

Net sales (JPY Mn)

1,079,500

Operating income (JPY Mn)

52,000

Ordinary income (JPY Mn)

51,500

Net income (JPY Mn)

40,650

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

DPS (JPY, post-split)

13.517.520.022.525.0

Total dividends paid (JPY Mn)

5,8767,1509,2819,5579,604

Share buybacks (JPY Mn)

6,0065,6628,00117,01823,037

Authorisation by Period

PeriodAuthorisationStatus

FY2025

¥17.0bn executed (incl. ToSTNeT-3)

Complete

8 Dec 2025 – 31 Jan 2026

Up to 3.5m pre-split shares / ¥8.0bn

Complete within FY2026's ¥23.0bn (cash basis)

5 Aug – 30 Sep 2026

¥3.0bn

—

Cancellation

Treasury shares cancelled in FY2026; issued shares 459.6m → 439.6m post-split basis

Complete

Credit Ratings

AgencyRating

R&I

A+ (long-term), a-1 (short-term)

Moody's / S&P / Fitch

No rating identified

Capital Instruments

InstrumentAmount (JPY Mn)Maturity bucket

Short-term loans

20,175

<1 year

Commercial paper

47,000

<1 year

Current portion of long-term loans

15,000

<1 year

Bonds

40,000—

Long-term loans

50,000

1 year

Lease liabilities (long-term)

16,077

1 year

Analyst Conclusions

Guidance and consensus

Company FY2027: sales ¥1.0tn (+2.8%), operating income ¥45.0bn (+0.6%; −9% excluding actuarial gains), NI ¥34.5bn (+4.2%), EPS ¥84.59, DPS ¥27. Under review at H1.

Consensus FY2027: OI ¥52.0bn (+16%), NI ¥40.65bn (+23%).

Plan FY2029: OI >¥50bn; ROE ≥9%; EPS +30% over three years.

Q1 FY2027 delivered 38% of full-year OI, so an upward revision at H1 is plausible. That depends on the durability of Middle East-driven price levels, which management itself expects to reverse.

Bull case

  1. AI-packaging leverage. Nagase ChemteX's Q1 FY2027 OI nearly doubled to ¥1.7bn at a 17% margin. If a-SMC scales beyond small-volume production, Electronics could re-rate the group mix toward specialty-materials multiples.

  2. Prinova repair. FY2027 guidance implies Prinova OI after amortisation of ¥5.1bn (+22%). The Nutrition loss is narrowing, and Solutions is growing. Every 1pt of Prinova margin is about ¥2.4bn of OI at FY2027 sales.

  3. Capital-return engine. A 100% total payout, ¥87.6bn of investment securities available to sell and a 30% EPS-growth commitment give a mechanical path to ROE of 9% or more, even with modest operating growth.

Bear case

  1. Earnings-quality and peak-cycle risk. FY2027 underlying guidance is −9% excluding the actuarial gain. Q1 strength came from crisis-driven pricing and inventory, and the subsequent reversal could produce inventory losses on a ¥195bn inventory base.

  2. China concentration. At 22.8% of sales, with semiconductor materials sold into China, export-control escalation could hit the highest-margin segment.

  3. Structural ROIC ceiling. About 5% ROIC on a ~¥577bn capital base, a ~129-day cash conversion cycle and Prinova's low margin mean much of the plan's ROE delivery is financial engineering (buybacks) rather than economic-profit growth.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Early Nov 2026H1 FY2027 results and full-year forecast reassessment (Middle East effects; potential upgrade toward consensus)
OngoingNaphtha and resin price trajectory; inventory levels and working-capital release
Ongoinga-SMC volume ramp; Nagase ChemteX capacity additions; Nagase Circrea integration
OngoingPrinova Nutrition break-even; logistics costs; US tariff policy on ingredients
OngoingDeployment of the ¥100bn growth envelope (semiconductor-materials M&A)
OngoingFurther buyback authorisations and cross-shareholding sales
Feb 2027Q3 FY2027 results
May 2027FY2027 results; first-year progress on Walk the Talk 2028; FY2028 guidance
OngoingUS–China export-control developments; USD/JPY and RMB/JPY

Analyst verdict

Nagase has done what it promised under ACE 2.0, and that is not trivial for a 190-year-old Japanese trading house. Operating income rose from ¥30.6bn in FY2024 to a record ¥44.7bn in FY2026. ROE moved from 5.9% to 8.0%. Gross margin expanded despite flat volumes, and shareholders received more than 100% of earnings for two consecutive years. The portfolio is clearly being reshaped toward proprietary manufacturing:

  • Nagase ChemteX's AI-packaging epoxies and the new a-SMC encapsulant

  • Nagase Circrea's circular high-purity chemicals

  • Nagase Diagnostics

The four-for-one split, a fourth independent director and the three-segment simplification show a management team focused on market valuation.

The equity story nevertheless remains a "good capital allocator in a low-return business" story rather than a structural compounder. Group ROIC of roughly 5% barely clears any reasonable cost of capital. Prinova, the largest single asset (¥214bn of sales), still earns roughly 2% after amortisation. The FY2027 guidance, read correctly, implies underlying operating profit down about 9%, flattered by a pension actuarial gain. The exceptional Q1 FY2027 was driven partly by a geopolitical price shock that management itself expects to reverse.

At ¥1,152 the stock trades at about 13.6x guided and about 11.6x consensus FY2027 EPS, 1.1x book and about 9.7x trailing EV/EBITDA, with a 2.3% yield and a mechanical buyback bid. That valuation is fair for a specialty distributor and leaves modest upside if the consensus ¥52bn operating income proves right. The H1 update in November is the key test of whether Q1 was structural or windfall.

Our stance: constructive but selective. The risk/reward favours accumulation on post-results weakness rather than chasing strength. The thesis should be monitored against three markers:

  • a-SMC volume scaling

  • Prinova margin progress toward 4% or more

  • working-capital discipline as commodity prices normalise

Failure on Prinova would cap the re-rating regardless of buybacks.


SOURCES (principal)

  1. Nagase & Co., Ltd., Consolidated Financial Statements for the Fiscal Year Ended March 31, 2026 (Kessan Tanshin), 7 May 2026 — finance-frontend-pc-dist.west.edge.storage-yahoo.jp/disclosure/20260507/20260507518029.pdf

  2. Nagase & Co., Ltd., FY2026 First Quarter Financial Briefing, 4 Aug 2026 — finance-frontend-pc-dist.west.edge.storage-yahoo.jp/disclosure/20260804/20260804508227.pdf

  3. Nagase & Co., Ltd., Notice of Revision of Full-Year Consolidated Earnings Forecast, 6 Nov 2025 — kabuyoho-sls-disclose.ifis.co.jp

  4. Yuho FY2026 extracts (corporate history, affiliates): Kitaishihon — kitaishihon.com/company/8012/story

  5. Yuho FY2026 extracts (segments, shareholders, board, remuneration): The-Shashi — the-shashi.com/tse/8012/

  6. S&P Global Market Intelligence data via StockAnalysis (income statement, balance sheet, cash flow) — stockanalysis.com/quote/tyo/8012/

  7. Kabuyoho / IFIS consensus and price data — kabuyoho.jp

  8. Matsui Securities and Traders.co.jp price data — finance.matsui.co.jp; traders.co.jp

  9. FilingReader summaries (H1 FY2026, FY2026 results, Walk the Talk 2028) — filingreader.com

  10. Houlihan Lokey transaction note (SACHEM Asia, US$101m) — hl.com

  11. SACHEM press release, 18 Mar 2025 — sacheminc.com

  12. Nagase Diagnostics press release, 1 May 2025 — group.nagase.com

  13. Prinova / Aplinova press release, 2 Apr 2025 — prezly CDN

  14. Nagase press releases via Kyodo News PR Wire (NWI, 27 May 2025; Pune, 1 Dec 2025)

  15. Envalith company overview and segments (summaries of Yuho/IR) — envalith.com/en/companies/8012

  16. Nagase CEO message (Apr 2023); notice of change of President (25 Jan 2023); ACE 2.0 plan document (2021); KPI notice (May 2022) — nagase.com

  17. j-lic.com (auditor, registered address)

  18. Inabata & Co. FY2026 results via Matsui, Yahoo Finance JP, Logmi and Gyokai Digest

  19. KnowESG (Sustainalytics), DitchCarbon, Rubber World (2022 carbon-neutral declaration), sustainabilityreports.com (Integrated Report 2025 summary)

  20. GlobalData company profile (Dodai Group stake; Nippon Express partnership) — globaldata.com

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / backgroundIndependentAGM approval

Kenji Asakura (朝倉研二)

Representative Director, Chairman (Board Chair)

Joined Nagase Apr 1978; President 2015–Mar 2023; Chairman from Apr 2023

No

95.10%

Hiroyuki Ueshima (上島宏之)

Representative Director, President & CEO

Joined Nagase Apr 1988; director since Jun 2022 (development); President & CEO since Apr 2023.

No

95.28%

Hiroshi Nagase (長瀬洋)

Director, Senior Adviser

Joined Apr 1977; President 1999–2015; later Chairman; founding-family member

No

98.61%

Tamotsu Isobe (磯部保)

Director, Executive Officer

Joined Apr 1992

No

99.33%

Yoshihisa Shimizu (清水義久)

Director, Executive Officer

Joined Apr 1987; formerly GM Corporate Management Dept. (2022)

No

99.33%

Ritsuko Nonomiya (野々宮律子)

Outside Director

Began career at Peat Marwick Main (now KPMG), Sep 1987

Yes

95.19%

Noriaki Horikiri (堀切功章)

Outside Director

Joined Kikkoman Apr 1974; former Kikkoman President & CEO (per analyst knowledge)

Yes

99.65%

Toshiaki Mikoshiba (神子柴寿昭)

Outside Director

Joined Honda Apr 1980; President of Honda Motor Europe; President & CEO of Honda North America (from 2016); elected 2023

Yes

99.66%

Eriko Sakurai (桜井恵理子)

Outside Director (new, Jun 2026)

—

Yes

99.58%

Executive Leadership Team

NameRoleSource

Natsuki Imamura

Executive Officer, GM Corporate Management Dept. (IR contact)

Kessan Tanshin FY2026

Kazuhiro Hanba

Executive Officer, Head of Corporate Management Division (Nov 2025)

Forecast revision notice, 6 Nov 2025

Kentaro Nagase

Executive Officer (from Apr 2023; New Value Creation Office)

Company notice, Jan 2023

Directors' Remuneration

CategoryHeadcountTotal (JPY Mn)Fixed (JPY Mn)Bonus (JPY Mn)Stock (JPY Mn)

Directors (excl. outside)

745020116820

Audit & Supervisory Board members

3505000

of which outside officers

3444400

Total

1050025116820

Directors' Remuneration (Annual)

MetricFY2022FY2023FY2024FY2025FY2026

Total officer remuneration (JPY Mn)

446548282490500

Major Shareholders

RankHolderStake (%)Shares (pre-split, thousand)
1

The Master Trust Bank of Japan (trust a/c)

11.7112,027
2

Custody Bank of Japan (trust a/c)

6.246,406
3

Nagase & Co. Employee/Business Partner Shareholding Association (長瀬産業自社株投資会)

4.464,576
4

Nippon Life Insurance

3.503,589
5

Reiko Nagase (founding family)

3.033,115
6

Shunzo Nagase (founding family)

2.622,688
7

Sumitomo Mitsui Trust Bank

2.582,653
8

State Street Bank and Trust Co. 505001

2.572,643
9

Nomura Custody Nominees (omnibus)

2.222,281
10

Sumitomo Mitsui Banking Corp.

2.132,188

Competitive Landscape

Competitors by Segment

SegmentDirect competitorsNotes

Chemicals / resins trading (Materials)

Inabata & Co. (8098); Chori (8014); CBC Co. (private); Sojitz Plastics / Sojitz; Toyota Tsusho (chemicals & electronics); Mitsubishi Corp. / Mitsui & Co. chemical units; Itochu Chemical Frontier; Okura Industrial trading peers

Inabata is the closest listed specialty-chemicals trading peer

Global specialty chemical distribution

Brenntag (DE); IMCD (NL); Azelis (BE); DKSH (CH, Performance Materials)

Larger, more acquisitive; higher margins at IMCD and Azelis

Semiconductor packaging materials (Nagase ChemteX)

Resonac (ex-Showa Denko Materials); Sumitomo Bakelite; Namics (private); Shin-Etsu Chemical (encapsulants); Henkel (adhesives/encapsulants)

Nagase ChemteX is a niche leader in liquid molding compounds

High-purity chemicals / developer (Nagase Circrea)

Tokuyama; Tama Chemicals; SACHEM (outside Asia); Kanto Chemical

TMAH supply and recycling niche

Electronics trading

Macnica Holdings; Ryoyo Ryosan; Inabata (information-electronics)

—

Food & nutrition ingredients (Prinova)

Brenntag Nutrition; IMCD Food & Nutrition; Azelis F&N; Glanbia Nutritionals; dsm-firmenich premix; Univar Solutions (private)

Prinova competes on breadth and premix/contract-manufacturing capability

Saccharides / bio-ingredients (Nagase Viita)

Cargill; Ingredion; Roquette; Hayashibara-legacy trehalose has few direct producers

Strong niche position in trehalose and pullulan

Diagnostics enzymes / reagents

Toyobo; Kikkoman Biochemifa; Roche CustomBiotech

—

Automotive materials (Mobility)

Toyota Tsusho; Inabata; Sojitz

—

Peer Comparison FY2024

CompanyFY / periodRevenueRevenue growthOperating marginNet marginR&D intensitySource / reliability

Nagase & Co.

FY ended Mar 2026

¥972.8bn

+2.9%4.6%3.4%—

Kessan Tanshin (primary)

Inabata & Co.

FY ended Mar 2026

¥832.7bn

-0.6%3.1%2.5%—

Inabata Kessan Tanshin via Matsui/Logmi (verified)

Brenntag SE

FY2024 (Dec)

~€16.2bn

~-7%

~7% (operating EBITA)

—

n/m

—

IMCD N.V.

FY2024 (Dec)

~€4.7bn

~+6%

~11% (operating EBITA)

—

n/m

—

“—” = not publicly disclosed.

Competitor Detail

Inabata & Co. metricFY2024FY2025FY2026

Net sales (JPY Mn)

766,022837,838832,745

Operating income (JPY Mn)

21,19025,82426,164

Net income (JPY Mn)

20,00019,83320,632

Recent Developments

--

Company Snapshot

$6,498.2M

Revenue

7,756

Employees

1832

Founded

Osaka, Japan

Headquarters

SWOT Analysis

Strengths

  • Record profitability with margin expansion. FY2026 gross profit grew 8.3% on 2.9% sales growth, and gross margin rose ~1.0pt to 19.3%. Q1 FY2027 gross margin reached 19.7% (Kessan Tanshin; Q1 Briefing).
  • High-margin captive manufacturing. Nagase ChemteX Group earned 35.5% gross and 11.5% operating margin in FY2026; Nagase Viita 40.3% gross and 16.5% operating margin before amortisation (Q1 Briefing).
  • AI-semiconductor exposure. Electronics & Energy operating income rose from ¥8.9bn (FY2024) to ¥14.9bn (FY2026), with an 8.6% margin and segment ROA of 13.3% (Yuho).
  • Balance-sheet strength. Equity ratio 48.8%, net D/E 0.34x, R&I A+ / a-1 rating, interest coverage 13.4x in FY2026.
  • Shareholder-return credibility. 17 consecutive projected annual dividend increases (DPS ¥10.00 in FY2018 to ¥27.00 forecast in FY2027, post-split). Total payout 105.4% (FY2025) and 100.7% (FY2026).
  • Diversification. No segment above 32% of sales. Life Sciences (31.8%) provides non-cyclical ballast against Electronics and Materials cyclicality (Yuho FY2026).
  • Supply-chain resilience. Q1 FY2027 record results were driven partly by sourcing alternative products during the Hormuz-linked naphtha shortage (Q1 Briefing).

Weaknesses

  • Low structural margins. Consolidated operating margin of 4.6% in FY2026, versus roughly 7% at Brenntag and 11% at IMCD (approx.).
  • Prinova underperformance. FY2026 operating income after amortisation was ¥4.2bn on ¥214.2bn sales (2.0%). A ~¥1.3bn bad-debt provision was taken in FY2025, and the Nutrition business was loss-making (Q1 and Q3 briefings).
  • ROIC near cost of capital. Analyst ROIC ~5.4% in FY2026; company forecast ROIC 5.2% (Integrated Report 2025).
  • Working-capital intensity. Cash conversion cycle ~129 days. Q1 FY2027 operating cash flow was −¥21.2bn on a ¥30.6bn working-capital build.
  • Low-quality elements in FY2027 guidance. ~¥4.0bn actuarial gain in operating income; underlying guidance OI is ¥40.9bn, −9% YoY (Q1 Briefing).
  • Mobility decline. Segment operating income fell 10.7% to ¥3.8bn in FY2026 (2.9% margin), the only declining segment (Yuho).
  • Governance below best practice. Outside directors 44% (not a majority); kansayaku model retained; founding-family members on the board.

Opportunities

  • Advanced packaging. a-SMC adopted for high-performance IC package substrates, with small-volume production started (Q1 FY2027). LMC demand from AI chips is rising.
  • Circular semiconductor chemicals. TMAH recycling and high-purity chemicals via Nagase Circrea (acquired for US$101m).
  • ¥100bn growth-investment envelope under Walk the Talk 2028, aimed at semiconductor materials and Prinova efficiency.
  • India and Global South. NWI JV, Pune branch, Dholera semiconductor logistics with Nippon Express, Aplinova in Brazil.
  • Cross-shareholding monetisation. Investment securities of ¥87.6bn at Mar 2026, with unrealised gains of ¥40.5bn net of tax in OCI, can fund buybacks.
  • Life-science manufacturing. Nagase Diagnostics and Prinova Solutions growth. Prinova FY2027 guidance: sales +13%, OI after amortisation +22%.

Threats

  • US–China tensions. Greater China is 22.8% of sales, and semiconductor materials sold into China are highlighted as a risk (Q1 Briefing; Envalith).
  • Commodity-price reversal. Q1 FY2027 gains came from "soaring market prices"; management is managing inventory "in preparation for future price declines" (Q1 Briefing).
  • Yen appreciation. FY2027 assumes USD/JPY 155 and RMB/JPY 22.5. RMB sensitivity is ¥400m of operating income per ¥1.
  • EV slowdown and automotive production polarisation (Q1 Briefing industry review).
  • Smartphone/PC weakness from memory shortages, affecting Nagase ChemteX mobile LMC demand (Q1 Briefing).
  • Prinova logistics-cost inflation and possible US tariffs on imported ingredients (Q1 FY2027 trading-profit decline of 40% in Life Sciences trading).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 Apr 2025Prinova acquires Aplinova (Brazil)Global South expansion in food ingredients
1 May 2025Nagase Diagnostics to join group from 1 Jul 2025 (205 employees)Life-science manufacturing build-out
8 May 2025FY2025 results: sales ¥945.0bn (+5.0%), OI ¥39.1bn (+27.6%), NI ¥25.5bn (+13.9%)Profit inflection; shareholder-return enhancement
27 May 2025Nagase Wahlee India JV announced (ops Jun 2025)Captures China/Taiwan supply-chain shift to India
2 Jun 2025SACHEM Asia acquisition closes (US$101m)Adds semiconductor high-purity chemicals manufacturing
–ToSTNeT-3 buyback of 1,361,600 pre-split sharesPart of the 100% total-payout commitment
1 Jul 2025Nagase Diagnostics consolidated—
22 Jul 2025Share price 52-week low ¥712.1 (split-adjusted)Trough before re-rating
5 Aug 2025Q1 FY2026 results—
6 Nov 2025H1 FY2026: sales ¥479.7bn (−0.3%), OI ¥21.1bn (flat), NI ¥15.1bn (−5.6%). Full-year OI guidance raised to ¥40.7bn; 4-for-1 split announced; buyback up to 3.5m shares / ¥8bn (8 Dec 2025–31 Jan 2026)Guidance upgrade; liquidity measures
6 Nov 2025Segment forecast revision: Life & Healthcare OI raised to ¥8.7bn; Mobility cut to ¥3.8bn; AM&P raised to ¥7.1bnShows the divergence between Life and Mobility
1 Dec 2025Nagase India opens Pune branchIndia coverage
Jan 2026SACHEM Japan Holding GK and SN Tech absorbed into SACHEM Japan GKIntegration
Jan 2026California biotech lab opened (robotics/AI)Innovation platform
Jan 2026Nippon Express partnership on Indian semiconductor-materials supply chain (Dholera)India semiconductor ecosystem (GlobalData)
5 Jan 20262026 YTD low ¥956.3—
5 Feb 20269M FY2026: record sales ¥724.1bn (+0.8%), OI ¥33.2bn (+7.1%), NI ¥24.9bn; gross margin +0.9ptROIC strategy visible in margins
Mar 2026SACHEM (Wuxi) renamed Nagase Circrea (Wuxi)Rebranding
1 Apr 20264-for-1 split effective; SACHEM Japan → Nagase Circrea; SACHEM Korea → Nagase Circrea Korea; three-segment structure beginsStructural reset
15 Apr 2026Then all-time high ¥1,257Re-rating
Apr 2026Partial stake in Dodai Group (GlobalData)Venture-style investment
Spring 2026Strait of Hormuz blockade causes naphtha shortage; Nagase sources alternatives via its global networkShort-term earnings windfall; supply-chain-resilience proof point
7 May 2026FY2026 record results: sales ¥972.8bn (+2.9%), OI ¥44.7bn (+14.5%), NI ¥33.1bn (+29.8%), ROE 8.0%. FY2027 guidance (OI ¥45.0bn); DPS ¥100 pre-split. "Walk the Talk 2028" launchedACE 2.0 targets met; new plan
8 May 2026Share price −7.1% (¥1,203.5 → ¥1,118)Market disappointed by flat guidance excluding actuarial gains
16–17 Jun 2026Yuho filed; 112th... AGM held 17 Jun 2026; board expanded to 4 outside directors (Eriko Sakurai added)Governance upgrade
4 Aug 2026Q1 FY2027: record sales ¥279.7bn (+18%), OI ¥17.0bn (+66%), NI ¥14.6bn (+95%). Guidance maintained pending H1 reassessment. ¥3.0bn buyback (5 Aug–30 Sep 2026)Strong start; Middle East tailwind
5 Aug 2026All-time / YTD high ¥1,306—
29 Sep 2026Close ¥1,152. Consensus FY2027 OI ¥52.0bn vs guidance ¥45.0bnStreet above company
Early Nov 2026 (scheduled)H1 FY2027 results with forecast reassessmentKey near-term catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Net sales rose from JPY 780.6 Bn in FY2022 to JPY 972.8 Bn in FY2026.
Nagase & Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (JPY Bn)FY2022FY2023FY2024FY2025FY2026
Net sales780.6912.9900.1945972.8
Gross profit139.5155.4164.7173.3187.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.